Behcet DiseaseNCT07662603
Behcet Disease Patients With Pulmonary Endoarterectomy: Outcomes of Program of Inspiratory Msucle Trianing
A study testing inspiratory muscle trianing in people with Behcet Disease, run by Cairo University at 1 site in Egypt.
Trial summary
physical complications are common in Behcet disease patients with pulmonary endoarterectomy, so outcomes of program of inspiratory msucle trianing must be investigated Read more about this study
- Who is it for?
- Ages 13 to 17 years
- Conditions the study is for
- Behcet Disease
- What is being tested?
- inspiratory muscle trianing
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteEgypt
- Study dates
- 6 May 2026to 6 Sep 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 13 to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- adlescent patients
- complain Behcet disease
- after pulmonary endoarterectomy
Who cannot join
- chronci cardiac diseases
- psychic disease
- mental disease
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
Cairo University
Giza, Dokki
ali ismail, lecturer, 02 01005154209, ali.mohamed@pt.cu.edu.eg
About this study
physical complications are common in Behcet disease patients with pulmonary endoarterectomy, so outcomes of program of inspiratory msucle trianing must be investigated
Read the detailed description
Forty Behcet disease patients with pulmonary endoarterectomy will be assigned to group I or Group II. the patients will be adolescents, 20 patients in the group. Group I will recive program of inspiratory msucle trianing for 12 weeks (one session daily, except the last two days of the week) Group II will act waitlist group.
- Conditions
- Behcet Disease
- Being tested
- inspiratory muscle trianing
- Medical subject headings
- Behcet Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
inspiratory muscle trianingOther
twenty Behcet disease patients with pulmonary endoarterectomy will be will recive program of inspiratory msucle trianing for 12 weeks (one session daily, except the last two days of the week)
| Study group | Role | What they receive |
|---|---|---|
| group number 1 | Experimental | twenty Behcet disease patients with pulmonary endoarterectomy will be will recive program of inspiratory msucle trianing for 12 weeks (one session daily, except the last two days of the week) Receives: Other: inspiratory muscle trianing |
| group number 2 | No intervention | twenty Behcet disease patients with pulmonary endoarterectomy will act as wailisting group for 12 weeks |
What is being measured
The primary outcome is the main question the study is designed to answer.
forced vital capacity
it si a pulmaonry fucntion test
Measured: it will be measured after 12 weeks
Secondary outcomes (9)
forced expiratory volume
it will be assessed in first second of expiration
Measured: It will be measured after 12 weeks
ratio of force vital capcity to first-second-expiratory forced expiration volume
it is a pulmoanry fucntion test
Measured: It will be measured after 12 weeks
fatigue severity scale
it will assess fatigue perception
Measured: It will be measured after 12 weeks
child health questainanire parent form assessment of phsyical summary
it is an assessment of quality of life
Measured: it will be measured after 12 weeks
child health questainanire parent form assessment of mental summary
it is an assessment of quality of life
Measured: It will be measured after 12 weeks
Ruffier index
it an indiactor for cariorespiratory fitness
Measured: It will be measured after 12 weeks
maxinmal inspiration pressure
it is an indicator for isnpiratory msucular stength
Measured: It will be measured after 12 weeks
maxinmal expiration pressure
it is an indicator for expiratory msucular stength
Measured: It will be measured after 12 weeks
six minute walk test
distance covered during this test will be assessed
Measured: It will be measured after 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jun 2026
- Study start6 May 2026
- Primary completion6 Sep 2026 (estimated)
- Study completion6 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Behcet DiseaseStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ali Mohamed Ali ismail, Cairo University
- Investigators
- Ali MA Ismail, lecturer, Principal investigator, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07662603
- Sponsor's protocol ID
- IRB000-14233-81
- Status last verified
- Jun 2026
- First submitted
- 17 Jun 2026
- Last updated
- 23 Jun 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Behcet Disease Patients With Pulmonary Endoarterectomy: Outcomes of Program of Inspiratory Msucle Trianing
- ClinicalTrials.gov ID
- NCT07662603
- Acronym / sponsor ID
- IRB000-14233-81
- Conditions
- Behcet Disease
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 6 May 2026 (actual)
- Primary completion
- 6 Sep 2026 (estimated)
- Study completion
- 6 Sep 2026 (estimated)
- First posted
- 23 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
physical complications are common in Behcet disease patients with pulmonary endoarterectomy, so outcomes of program of inspiratory msucle trianing must be investigated
Detailed description
Forty Behcet disease patients with pulmonary endoarterectomy will be assigned to group I or Group II. the patients will be adolescents, 20 patients in the group. Group I will recive program of inspiratory msucle trianing for 12 weeks (one session daily, except the last two days of the week) Group II will act waitlist group.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| group number 1 | Experimental | Other: inspiratory muscle trianingtwenty Behcet disease patients with pulmonary endoarterectomy will be will recive program of inspiratory msucle trianing for 12 weeks (one session daily, except the last two days of the week) |
| group number 2 | No intervention | –twenty Behcet disease patients with pulmonary endoarterectomy will act as wailisting group for 12 weeks |
Who may qualify
- Ages
- 13 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (3 listed)
- adlescent patients
- complain Behcet disease
- after pulmonary endoarterectomy
Key exclusion criteria (3 listed)
- chronci cardiac diseases
- psychic disease
- mental disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| inspiratory muscle trianingtwenty Behcet disease patients with pulmonary endoarterectomy will be will recive program of inspiratory msucle trianing for 12 weeks (one session daily, except the last two days of the week) | Other | group number 1 |
Primary outcome
forced vital capacity
Time frame: it will be measured after 12 weeks
it si a pulmaonry fucntion test
9 secondary outcomes
forced expiratory volume
Time frame: It will be measured after 12 weeks
ratio of force vital capcity to first-second-expiratory forced expiration volume
Time frame: It will be measured after 12 weeks
fatigue severity scale
Time frame: It will be measured after 12 weeks
child health questainanire parent form assessment of phsyical summary
Time frame: it will be measured after 12 weeks
child health questainanire parent form assessment of mental summary
Time frame: It will be measured after 12 weeks
Ruffier index
Time frame: It will be measured after 12 weeks
maxinmal inspiration pressure
Time frame: It will be measured after 12 weeks
maxinmal expiration pressure
Time frame: It will be measured after 12 weeks
six minute walk test
Time frame: It will be measured after 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jun 2026.
Related trials for Behcet Disease
RecruitingPhase 3
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
Behçet's Disease, Juvenile Psoriatic Arthritis
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Not yet recruitingObservational study
Serum EBI-3 Protein Levels in Behçet's Disease
Behçet Disease
Not yet recruitingPhase 2
Corticotropin for Behçet's Disease: A Multicenter Randomized Controlled TrialAcronym.
Behçet's Syndrome, Behçet's Syndrome (BS)
RecruitingPhase 2
Baricitinib in the Treatment of Intestinal Behçet's Syndrome
Behcet Syndrome, Intestinal Type
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ali MA Ismail, lecturer principal investigator
Cairo University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing inspiratory muscle trianing in people with Behcet Disease, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ali MA Ismail, lecturer (01005154209, ali.mohamed@pt.cu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
forced vital capacity (time frame: it will be measured after 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jun 2026.